CDEK
← All drugs Report issue

piperaquine

Small moleculeexperimental

Piperaquine is an antiparasitic drug used in combination with dihydroartemisinin to treat malaria. Piperaquine was developed under the Chinese National Malaria Elimination Programme in the 1960s and was adopted throughout China as a replacement for the structurally similar antimalarial drug chloroquine. Due to widespread parasite resistance to piperaquine, the drug fell out of use as a monotherapy, and is instead used as a partner drug for artemisinin combination therapy. Piperaquine kills parasites by disrupting the detoxification of host heme. — Wikipedia

Clinical trial activity

155 trials · 195 clinical orgs · 0 marketing orgs

Phase 1
20
Phase 2
65
Phase 3
57
Phase 4
46

Earliest trial started May 1, 2003 (NCT00313872)

Timeline

2000s

  1. Jan 1, 2003

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2007

    Earliest Phase 2 Sponsor(trial)

2010s

  1. Jan 1, 2012

    Earliest Phase 1 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

Clc1ccc2c(N3CCN(CCCN4CCN(c5ccnc6cc(Cl)ccc56)CC4)CC3)ccnc2c1.O=P(O)(O)O.O=P(O)(O)O.O=P(O)(O)O.O=P(O)(O)O
Mol. weight
927.5 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 1,3-bis(1-(7-chloro-4'-quinolyl)-4'-piperazinyl)propane
  • 1,3-bis(4-(7'-chloro-4'-quinoline)-1-piperazine)
  • dihydroartemisinin mixture with piperaquine tetraphosphate
  • piperaquine
  • piperaquine
  • piperaquine
  • piperaquine
  • piperaquine
  • piperaquine
  • piperaquine phosphate
  • piperaquine phosphate
  • piperaquine phosphate
  • piperaquine phosphate
  • piperaquine phosphate hydrate
  • piperaquine tetraphosphate
  • piperaquine tetraphosphate
  • piperaquine tetraphosphate
  • piperaquine tetraphosphate /artenimol
  • piperaquinoline
  • quinoline, 4,4'-(1,3-propanediyldi-4,1-piperazinediyl)bis(7-chloro-)

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07246525Phase 4Dec 1, 2025Government of Uganda, Infectious Disease Institute, Kampala, Uganda, National Institute of Allergy and Infectious Diseases (NIAID), University of California, San Francisco
NCT07021430Early Phase 1 (Phase 1)Oct 31, 2025National Institute of Allergy and Infectious Diseases (NIAID), University of North Carolina at Chapel Hill
NCT06962319Phase 3Sep 30, 2025Medicines for Malaria Venture, University of Liverpool
NCT07082205Phase 3May 2, 2025Centers for Disease Control and Prevention (CDC), National Institute of Allergy and Infectious Diseases (NIAID), University of Liverpool
NCT06870344N/AMar 12, 2025Mbarara University of Science and Technology, National Institute of Allergy and Infectious Diseases (NIAID), North Carolina State University, University of North Carolina at Chapel Hill
NCT06083688Phase 4Oct 31, 2024Kamuzu University of Health Sciences, University of Liverpool
NCT07281443N/ASep 23, 2024Cheikh Anta Diop University, Senegal, Government of France, Government of Senegal
NCT06516042Phase 3Aug 21, 2024Government of Ethiopia, PATH
NCT06347471Phase 4May 28, 2024Infectious Disease Institute, Kampala, Uganda, Radboud University, University of London
NCT06172686Phase 1Jan 9, 2024Ifakara Health Institute, University of Oxford
NCT06068530Phase 4Nov 1, 2023Mahidol University, University of Oxford
NCT05930782Phase 1Aug 14, 2023Ifakara Health Institute, Medicines for Malaria Venture
NCT05946642Phase 3Jul 15, 2023Malaria Consortium
NCT05788094Phase 4Jun 26, 2023Mahidol University
NCT05980156Phase 4Feb 13, 2023Doris Duke Charitable Foundation, Kamuzu University of Health Sciences, University of Maryland
NCT05829187Phase 2Nov 1, 2022Pancasila University
NCT05426434Phase 3Aug 31, 2022Curtin University, Government of Papua New Guinea, Menzies School of Health Research, University of Liverpool, University of Melbourne
NCT05252845Phase 2Jul 31, 2022Mahidol University, University of Oxford
NCT05323721Phase 4Jun 1, 2022Government of Uganda, Malaria Consortium
NCT05340153Phase 4Apr 11, 2022Association Camerounaise pour le Marketing Social (ACMS), Cameroon, Government of Cameroon, Impact Malaria, Cameroon, University of Yaounde
Showing 20 of 155 trials
Page 1 / 8

Organizations

Research & Development (195)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
University of OxfordAcademic/Hospital242252007
University of LondonAcademic/Hospital221542007
Mahidol UniversityAcademic/Hospital18152007
University of California, San FranciscoAcademic/Hospital161442007
Medicines for Malaria VentureAcademic/Hospital151022012
University of LiverpoolAcademic/Hospital15932007
Centers for Disease Control and Prevention (CDC)Government14242007
Makerere UniversityAcademic/Hospital12222007
Kenya Medical Research InstituteAcademic/Hospital10342012
Radboud UniversityAcademic/Hospital8342009
Institute of Tropical Medicine, BelgiumAcademic/Hospital7332003
National Institute for Medical Research, TanzaniaGovernment7342010
National Institute of Allergy and Infectious Diseases (NIAID)Government7142014
University of MalawiAcademic/Hospital7232010
National Institutes of Health (NIH)Government6022010
University of AntwerpAcademic/Hospital6122003
Wellcome TrustAcademic/Hospital6042004
Bill and Melinda Gates FoundationAcademic/Hospital5022010
Infectious Disease Institute, Kampala, UgandaAcademic/Hospital5122014
Malaria Research and Training Center, Bamako, MaliAcademic/Hospital5032008
195 organizations
Page 1 / 10